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Immunodeficiency is associated with higher cancer incidence. However, it is unknown whether there is a link between
immunodeficiency and development of multiple primary malignancies. In the present study we analyse this link focusing on
kidney-transplanted patients, as they are at higher risk of developing cancer due to the chronic assumption of immunosuppressants.
We followed up 1200 patients who underwent kidney transplantation between 1980 and 2012. A total of 77/1200 kidney-
transplanted patients developed cancer and 24 of them developed multiple cancers. Most multiple cancers were synchronous with
a nonsignificant association between cancer and rejection episodes. In the general cancer population, one-ninth of patients are at
higher risk of developing a second tumor over a lifetime; hence it would be reasonable to conclude that, from a merely theoretical
and statistical viewpoint, long-term transplanted patients potentially have a higher risk of developing MPMs. However, data did
not confirm this assumption, probably because these patients die before a second primary malignancy appears. Despite many
observations on the increased incidence of different tumor types in immunodeficient patients and despite immunosuppression
certainly being a predisposing factor for themulticancer syndrome, data so far are not robust enough to justify a correlation between
immunodeficiency and multiple primary malignancies in transplanted patients.
1. Introduction
Renal transplantation is the gold standard procedure for
patients with end-stage renal diseases.The increasing success
of such an approach is partly due to the use of increasingly
active immunosuppressive drugs, which have largely lowered
the rate of rejection and improved outcome [1]. However,
the chronic use of immunosuppressive drugs leads to an
increased cancer incidence [2]. A link between cancer devel-
opment and immunosuppression in transplanted patients is
well recognized. Over the past decades, a growing body of
evidence has emerged demonstrating the dual role of the
immune system in cancer, being involved both in tumor
development (via chronic inflammation through the innate
immune system) and in tumor elimination and control
(through the adaptive immune system) [3]. As an exam-
ple, renal cell carcinoma has been traditionally considered
immunogenic, as it does occur at a higher incidence in
immunosuppressed patients [4]. Also, this tumor type is
traditionally considered more responsive to immunotherapy.
Therefore, it is now well recognized that immunosuppressive
drugs used in transplanted patients may induce immune
defects, thus compromising the immune response and facil-
itating the development of a secondary immunodeficiency
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(ID) which can ultimately ease cancer onset [5]. Also,
the incidence of multiple primary malignancies (MPMs)
is increasing in the general population and it is expected
to further increase in the coming years. The definition of
MPMs requires that each tumor be a solid tumor, have a
histopathological diagnosis of malignancy, be topographi-
cally distinct from another one, and not include tumor that
are metastases of the primary. In terms of time, they are
classified as simultaneous (i.e., both tumors appear at the
same time), synchronous (i.e., the second tumor appears
within six months from the first tumor), and metachronous
(i.e., the second tumor appearsmore than sixmonths after the
first tumor) [6]. Having said that, it has to be considered that
should a transplanted patient develop a tumor, recover from
it, and continue to receive immunosuppressive treatment, the
risk of developing MPMs is potentially higher as compared
to the general population [7]. It is in this perspective that
the problem of MPMs in transplanted patients should be
considered. In this paper we focus on the link between
secondary immunodeficiency and the onset of MPMs in
transplanted patients, who are—by definition—patients at
higher risk of developing cancer due to the chronic assump-
tion of immunosuppressants.
To test the relationship between immunosuppression and
MPMs, we specifically selected kidney-transplanted patients
for several reasons. Firstly, among solid organ transplanted
patients, kidney recipients represent the most numerous
group, with the longest follow-up (kidney transplantation
was the first solid organ transplant carried out; from a
single cadaver donor it is generally possible to obtain two
kidneys for two different kidney recipients; living kidney
donation is a perfectly codified procedure which is carried
out worldwide).Therefore, this is a representative population.
Secondly, the median overall survival of kidney transplant
recipients is long (more than 10 years) and, accordingly,
so is the exposure to immunosuppressive drugs; hence, in
these patients it is possible to evaluate whether there is
a correlation between immunosuppression and cancer(s)
development over an adequate timeframe. Thirdly, after
kidney transplantation, immunosuppressants are generally
used at full dosage, thus making it possible to evaluate their
real effects on tumorigenesis. Last but not least, in this
population, transplanted organ failure does not inevitably
lead to death, as it is possible to return to dialysis. Therefore,
in these patients, the natural history of the disease may be
also evaluated after reduction/modification/interruption of
immunosuppressive drugs. For all the above-mentioned rea-
sons, we analyzed a consecutive series of patients undergoing
kidney transplantation at our institute.
2. Material and Methods
Through the analysis of medical records collected in our
department, we retrospectively examined 1200 kidney-
transplanted patients (745 male and 455 female) followed
up at Federico II University between 1980 and 2012. The
median follow-up was 10 years and the average graft sur-
vival 8 years. Patients’ age ranged between 18 and 65 years
and they were homogenous for donor/recipient immunol-
ogy (e.g., mismatch index), number of rejection events,
and immunosuppressive therapy. In our population, differ-
ent drugs and associations were used taking advantage of
their different mechanisms of actions: corticosteroids (the
oldest immunosuppressants), azathioprine (an old antipro-
liferative immunosuppressive drug), calcineurin inhibitors
(cyclosporine and tacrolimus are the most used as main-
tenance therapy; they primarily suppress the activation of
T lymphocytes by inhibiting the production of cytokines,
specifically IL-2), basiliximab (an IL-2 receptor antagonist
generally used as induction therapy), mycophenolate (a new
antiproliferative agent that interferes with DNA replication,
producing cytostatic effects on both T and B cells; it is
generally used as a “third agent” in triple immunosuppressive
regimens), mammalian target of rapamycin inhibitors (also
calledm-TOR inhibitors; they usually represent an alternative
to the long-term calcineurin inhibitor-based regimen and
its side effects). Drugs and associations have varied over
time. In general we used corticosteroids and azathioprine
from 1980 to 1984; corticosteroids, calcineurin inhibitors, and
azathioprine from 1984 to 1998; corticosteroids, calcineurin
inhibitors, basiliximab, mycophenolate, and mammalian tar-
get of rapamycin from 1998 to 2013. We did not at any time
use thymoglobulin.
3. Results
Among 1200 kidney-transplanted patients, 77 patients (6.4%)
[57 males (4.7%) and 20 females (1.7%)], developed a cancer.
A total of 53 patients (4.4% of global series and 69% of cancer
patients) developed a single cancer. A total of 20 patients
were diagnosed with a skin cancer (including melanoma)
and 33 patients with no skin cancer, representing 1.7% and
2.7% of global series and 26% and 43% of cancer patients,
respectively. It is worth noting that 24 patients (2% of global
series and 31% of cancer patients) presented with multiple
cancers: 20 multiple skin cancers (including melanoma) and
4 solid MPMs, representing 1.6% and 0.3% of global series
and 25.9% and 5.1% of cancer patients, respectively (Table 1).
With regard to the latter group, we observed the following
associations: prostate/kidney cancer (synchronous, surgically
treated, 2-year disease-free interval); Kaposi sarcoma/gastric
MALToma (metachronous, medical and surgical treatment,
1-year disease-free interval, exitus at 18 months); lung
cancer/squamous skin carcinoma (metachronous, medical
and surgical treatment, disease-free at 8 months, exitus at
14 months), and colon cancer/squamous skin carcinoma
(metachronous, surgically treated, 18-month disease-free
interval). Multiple cancer associations and their onset time
are detailed in Figures 1 and 2. Data on the association
between cancer and rejection episodes are not significant:
rejection episodes were only found in four patients and only
one of them developed a second cancer.
4. Discussion
Today the high standards in surgical, anaesthesiological,
and intensive-care procedures as well as in the clinical
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8%
17%
67%
8%
Cancer associations
2 multiple no skin malignancies:
MALToma + Kaposi
Prostata + kidney
4 melanoma + skin malignancies 16 multiple skin malignancies
2 no skin malignacies (lung and
colon) + skin malignancies
Figure 1: Cancers associations among 24 patients in 1200 kidney-
transplant patients
13 simultaneous/synchronous
Onset time
11 multiple skin malignancies
1 prostate + kidney malignancies
1 melanoma + skin malignancies
11 metachronous
5 multiple skin malignancies
3 melanoma + skin malignancies
1 lung + skin malignancies
1 MALToma + Kaposi malignancy
1 colon + skin malignancies
54%
46%
Figure 2: Onset time of MPMs among 24 patients in 1200 kidney-
transplant patients
management of patients undergoing transplantation enable
extremely positive results to be obtained in terms of short-
and medium-term survival for both organs and patients [8–
13]. However, these results have been partially nullified by
the long-term complications reported in these patients, espe-
cially the development of cancer. Incidence, aggressiveness,
and worse prognosis of tumors appear to be remarkably
increased in this group of patients as compared to the general
population of corresponding age [7, 14–16]. It has been
calculated that tumor prevalence at 10 years after kidney
transplant ranges from 20% to 30%, with peaks also over
45% at 20 years [16–21]. Among organ transplant recipients
the main factor facilitating cancer onset is certainly the
immunosuppressive treatment. Indeed, the neoplastic risk is
also increased in people treated with immunosuppressants
for reasons other than transplantation [20]. Besides the
indirect oncogenic effect exerted by all immunosuppressive
drugs, which alter the immune response, recent studies
have shown that some immunosuppressants (i.e., calcineurin
inhibitors, azathioprine, and thymoglobulin) exert a direct
oncogenic effect. Calcineurin inhibitors promote oncogen-
esis, neoplastic growth, and metastasization by inhibiting
DNA repair and apoptosis and by stimulating the production
of transforming growth factor-beta (TGF-beta) and vascular
endothelial growth factor (VEGF). Azathioprine and its
derivatives are able to increase DNA damage caused by UV
and to inhibit DNA repair. Thymoglobulin seems to foster
genetic mutations induced by oncoviruses (Figure 3). In this
context, it is worth noting that, in transplanted patients, some
tumor types may show a regression if immunosuppressive
therapy is withdrawn or changed/enriched with drugs such
as mTOR inhibitors and mycophenolate [22, 23]. However,
while the use ofmycophenolatewas associatedwith a reduced
cancer incidence, probably because its administration is
correlated to calcineurin inhibitor dose reduction, mTOR
inhibitors have shown a direct antineoplastic effect. These
properties—together with a reduced nephrotoxicity—have
led to an extended use of these drugs [24–35].
However, in transplanted patients, immunosuppressive
therapy is essential to avoid graft rejection, which ultimately
results in reduced morbidity and mortality. There is a huge
variability among different classes of immunosuppressive
drugs, which work through different mechanisms on the
immune system. When analyzing the association between
immunosuppressive therapy and increased cancer risk, dif-
ferent aspects have to be considered, such as the duration of
immune suppressive therapy, the intensity of treatment, and
the drug(s) used. Yet, such a huge variability in terms of clin-
ical studies’ fragmentation, uniqueness of each single patient,
different therapeutic approaches in different transplant cen-
ters, the switch from one immunosuppressive protocol to
another, and—last but not least—the pressure exercised by
pharmaceutical firms has led to contrasting results. Also, it is
worth remembering that the lifespan of transplanted patients
is longer; accordingly the time frame these people stay on
immunosuppressive treatment is longer too, with augmented
exposure to oncogenic factors and viral infections (Figure 4).
Furthermore, transplanted patients nowadays have a longer
life expectancy andmay reach the age at which the neoplastic
risk is naturally higher, when the transplant is not already
performed in aged people [19]. Overall, the increased cancer
risk after renal transplantation is now well recognized [36–
40]. So, the association between pharmacological immune
suppression and increased risk of cancer continues to be
a much-discussed topic [41]. It has been calculated that if
malignant tumors carried a lower mortality rate and were
more uniformly distributed in the general population, we
could still expect to find that 1 in 9 cancer patients would
develop a second cancer over a lifetime and that within this
group 1 in 27 patients will probably develop a third primary
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Hepatitis B
virus
Hepatitis C
virus
Hepatocellular
carcinoma
Brain 
tumours
Mesotheliomas
Merkel cell
carcinoma
Human 
polyomaviruses
(BKV, 
JCV, 
SV40, and
MCV)
Human T-cell
lymphotropic virus-1 
T-cell
leukemiaGastric
cancer
Helicobacter
pylori
Kaposi’s
Sarcoma
Lymphomas
Human herpes
virus (HHV8)
Human
papillomaviruses
(HPV)
Cervical
carcinoma
Non-melanoma 
skin cancer
Anogenital cancer
Nasopharyngeal
carcinoma
PTLD
Epstein–Barr
virus
(HTLV-1)
Figure 4: Oncoviruses and potentially related cancers.
6 BioMed Research International
cancer [6, 41–46]. This statistical projection obviously refers
to the general population. Therefore, it would be logical to
conclude that, from a merely theoretical and probabilistic
point of view, immunocompromised patients potentially
have a higher risk of developing MPMs [6, 24, 42, 46–48].
Transplanted patients treated with immunosuppressants may
develop multiple cancers in three different conditions: (1)
patients with a previous diagnosis of cancer who undergo
transplantation and, afterwards, present with a new cancer
during follow-up; (2) patients with a previous diagnosis
of cancer who undergo transplantation and then present
with a new cancer transmitted by the donor; (3) patients
developing MPMs after transplantation (those reported in
our study). But real life differs from theory, even when the
theory has valid bases. To the best of our knowledge, only
one study has specifically looked at the incidence of MPMs
in transplanted patients [49]. In this study, transplanted
patients did not show a statistically significant higher risk of
developingMPMs as compared to the corresponding general
population. Also, our experience together with a careful
review of the literature does not support the hypothesis that
immunocompromised patients are more likely to develop
MPMs. The reasons for this might simply lie in the fact that
kidney-transplanted patients probably die before a new “sec-
ond primary malignancy” appears or, alternatively, returning
to dialysis, they interrupt immunosuppressive therapy, thus
limiting the exposure to oncogenic effects of such drugs
over time. Furthermore, it is very hard to find transplanted
patients surviving a first cancer who keep on taking immune
suppressive treatment long enough to develop a second
primary cancer as a consequence of iatrogenic immune
deficiency. Indeed, until recently, kidney transplant recipients
who developed a tumor were treated according to medi-
cal/surgical approaches, which included—among others—
immunosuppressant withdrawal and, accordingly, return to
dialysis. Nowadays, the chance to have recourse to immuno-
suppressants such as mycophenolate and mTOR inhibitors
has allowed a large number of kidney-transplanted patients
who develop a tumor to recover by maintaining the function
of the transplanted organ. Hence, we are observing a group
of kidney-transplanted patients at higher risk of developing
a second tumor, as they recovered from the first one with-
out interrupting immunosuppressive therapy. However, the
follow-up of these patients is still limited; therefore, it is not
yet possible to evaluate the actual incidence of second tumors.
5. Conclusions
Despitemany observations regarding the increased incidence
of different tumor types in immunosuppressed patients and
despite the fact that immunosuppression is a predisposing
factor for multicancer syndrome, at least theoretically, so
far there are no significant statistical data indicating a clear
correlation between immunosuppression and MPMs. We
may therefore assume that it is hard to diagnose a second
cancer in immunocompromised patients because of their
shorter life expectancy. From the few reports found in the
literature and from our experience, we can conclude that
MPMs in immunosuppressed patients are more frequently
simultaneous/synchronous, usually have a viral etiology, and
regard the same organ or tissue, the skin is the most affected
tissue with a predominance of spinocellular carcinomas over
basocellular carcinomas (exactly the opposite of what is
observed in the general population), and at least one cancer
is readily detectable (e.g., skin cancer), thereby facilitating
an early diagnosis and treatment. It is our opinion that the
treatment ofMPMs in immunosuppressed patients should be
as intensive as possible, in order to obtain a complete recov-
ery. Moreover, it might be useful to suspend the immunosup-
pressive treatment or switch to other drugs such as m-TOR
inhibitors; this therapeutic approach has so far yielded good
results. In conclusion, available clinical and epidemiological
data allow immunosuppression to be considered as a cancer
risk factor. However, so far there is no sufficient evidence to
conclude that immunosuppression eases the onset of MPMs.
Hence, even if MPMs do not seem to be a real problem
today, theymay become an important issue in the near future,
when new treatments and stricter follow-up guarantee longer
life expectancy in immunosuppressed patients diagnosed
with cancer. Therefore, in potentially immunocompromised
patients (e.g., kidney transplant candidates), great relevance
must be given to preventive measures against oncoviral
infections (e.g., a vaccination program, as has already been
established for HBV and HPV); implementation of proce-
dures aiming at reducing the exposure to environmental
oncogenic factors (e.g., drugs, cigarette smoking, alcohol, sun
exposure, etc., as is already recommended to our patients);
strict follow-up programs with special attention to appa-
ratus/organs (e.g., genitourinary, skin, thyroid, liver, blood,
and bones) at higher cancer risk in such patients and—last
but not least—it is important to try to reduce the dosage of
immunosuppressive drugs as much as possible (especially for
calcineurin inhibitors, azathioprine, and thymoglobulin, for
which a direct oncogenic effect has been proven), without
exposing the patient to the risk of graft rejection. This
paradigm should aim at immunomodulation rather than
immunosuppression, which might be the true gold standard
of such a therapy.
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